Storia in 5 fonti

Biohaven's Ratty Setback; How Xenon Benefits

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 g fa

Biohaven's Ratty Setback; How Xenon Benefits

Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

originale

Timeline cronologica

giovedì 10 settembre 2026·biopharmadive.com
FDA places partial hold on Biohaven’s epilepsy drug
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
giovedì 10 settembre 2026·investors.com
Biohaven's Ratty Setback; How Xenon Benefits
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment.

benzinga.com

1 g fa

Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)

Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.

Leggi questa versione → originale

biopharmadive.com1 g fa

FDA places partial hold on Biohaven’s epilepsy drug

Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

Leggi questa versione → originale

morningstar.com43 min fa

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)

Leggi questa versione → originale

endpoints.news1 g fa

FDA places partial hold on Biohaven's ion channel drug

An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety data, Biohaven revealed in an SEC filing.

Leggi questa versione → originale

giovedì 10 settembre 2026·

endpoints.news

FDA places partial hold on Biohaven's ion channel drug

An epilepsy study of the experimental drug called BHV-7000 was paused after regulators requested more information about preclinical safety data, Biohaven revealed in an SEC filing.

giovedì 10 settembre 2026·

benzinga.com

Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN)

Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.

venerdì 11 settembre 2026·

morningstar.com

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)